587 related articles for article (PubMed ID: 23123095)
1. An expanding range of targets for kynurenine metabolites of tryptophan.
Stone TW; Stoy N; Darlington LG
Trends Pharmacol Sci; 2013 Feb; 34(2):136-43. PubMed ID: 23123095
[TBL] [Abstract][Full Text] [Related]
2. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
Sas K; Robotka H; Toldi J; Vécsei L
J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
[TBL] [Abstract][Full Text] [Related]
3. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
4. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid levels of kynurenine pathway metabolites in patients with eating disorders: relation to clinical and biochemical variable.
Demitrack MA; Heyes MP; Altemus M; Pigott TA; Gold PW
Biol Psychiatry; 1995 Apr; 37(8):512-20. PubMed ID: 7542489
[TBL] [Abstract][Full Text] [Related]
6. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases.
Lovelace MD; Varney B; Sundaram G; Lennon MJ; Lim CK; Jacobs K; Guillemin GJ; Brew BJ
Neuropharmacology; 2017 Jan; 112(Pt B):373-388. PubMed ID: 26995730
[TBL] [Abstract][Full Text] [Related]
7. Tryptophan metabolites and brain disorders.
Stone TW; Mackay GM; Forrest CM; Clark CJ; Darlington LG
Clin Chem Lab Med; 2003 Jul; 41(7):852-9. PubMed ID: 12940508
[TBL] [Abstract][Full Text] [Related]
8. New insights into tryptophan and its metabolites in the regulation of bone metabolism.
Michalowska M; Znorko B; Kaminski T; Oksztulska-Kolanek E; Pawlak D
J Physiol Pharmacol; 2015 Dec; 66(6):779-91. PubMed ID: 26769827
[TBL] [Abstract][Full Text] [Related]
9. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
Maes M; Mihaylova I; Ruyter MD; Kubera M; Bosmans E
Neuro Endocrinol Lett; 2007 Dec; 28(6):826-31. PubMed ID: 18063923
[TBL] [Abstract][Full Text] [Related]
10. G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast.
Cosi C; Mannaioni G; Cozzi A; Carlà V; Sili M; Cavone L; Maratea D; Moroni F
Neuropharmacology; 2011 Jun; 60(7-8):1227-31. PubMed ID: 21110987
[TBL] [Abstract][Full Text] [Related]
11. A review of chromatographic methods for bioactive tryptophan metabolites, kynurenine, kynurenic acid, quinolinic acid, and others, in biological fluids.
Fukushima T; Umino M; Sakamoto T; Onozato M
Biomed Chromatogr; 2022 May; 36(5):e5308. PubMed ID: 34978092
[TBL] [Abstract][Full Text] [Related]
12. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.
Schwarcz R; Pellicciari R
J Pharmacol Exp Ther; 2002 Oct; 303(1):1-10. PubMed ID: 12235226
[TBL] [Abstract][Full Text] [Related]
13. The analgesic effects of tryptophan and its metabolites in the rat.
Heyliger SO; Goodman CB; Ngong JM; Soliman KF
Pharmacol Res; 1998 Oct; 38(4):243-50. PubMed ID: 9774487
[TBL] [Abstract][Full Text] [Related]
14. Chronic Mild Stress Alters Kynurenine Pathways Changing the Glutamate Neurotransmission in Frontal Cortex of Rats.
Martín-Hernández D; Tendilla-Beltrán H; Madrigal JLM; García-Bueno B; Leza JC; Caso JR
Mol Neurobiol; 2019 Jan; 56(1):490-501. PubMed ID: 29725904
[TBL] [Abstract][Full Text] [Related]
15. Alterations of the tryptophan--nicotinic acid metabolism in vitiligo.
De Antoni A; Cardin Dè Stefani EL; Costa C; Vanzan S; Allegri G
Acta Vitaminol Enzymol; 1982; 4(3):237-43. PubMed ID: 7148608
[TBL] [Abstract][Full Text] [Related]
16. Kynurenic acid antagonists and kynurenine pathway inhibitors.
Stone TW
Expert Opin Investig Drugs; 2001 Apr; 10(4):633-45. PubMed ID: 11281814
[TBL] [Abstract][Full Text] [Related]
17. Kynurenic acid attenuates NMDA-induced pial arteriolar dilation in newborn pigs.
Bari F; Nagy K; Guidetti P; Schwarcz R; Busija DW; Domoki F
Brain Res; 2006 Jan; 1069(1):39-46. PubMed ID: 16388784
[TBL] [Abstract][Full Text] [Related]
18. Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors.
Fazio F; Lionetto L; Curto M; Iacovelli L; Copeland CS; Neale SA; Bruno V; Battaglia G; Salt TE; Nicoletti F
Neuropharmacology; 2017 Jan; 112(Pt B):365-372. PubMed ID: 27342123
[TBL] [Abstract][Full Text] [Related]
19. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
Fujigaki H; Yamamoto Y; Saito K
Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
[TBL] [Abstract][Full Text] [Related]
20. Prenatal inhibition of the tryptophan-kynurenine pathway alters synaptic plasticity and protein expression in the rat hippocampus.
Forrest CM; Khalil OS; Pisar M; Darlington LG; Stone TW
Brain Res; 2013 Apr; 1504():1-15. PubMed ID: 23353758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
